Das Rennen läuft / VERTEX +14% - 500 Beiträge pro Seite

[sunset01]

GSK und Vertex erhalten FDA-Zulassung für Lexiva
Die britische GlaxoSmithKline Plc., Europas größter Pharmakonzern, und das US-Biotechnologieunternehmen Vertex Pharmaceuticals Inc. erhielten von der US-Gesundheitsbehörde FDA die Marktzulassung für ihr neues HIV-Medikament Lexiva.

Nun darf das Arzneimittel in Kombination mit anderen HIV-Präparat eingesetzt werden. Lexiva, das bisher unter der Bezeichnung 908 bekannt war, gehört zur Klasse der Protease-Hemmstoffe, die den Aids verursachenden HIV-Virus unterdrücken.

Dieses neue Produkt habe den Vorteil, dass Patienten eine deutlich geringere Zahl von Tabletten einnehmen müssen, als bei der Behandlung mit anderen Medikamenten erforderlich ist.

Die Aktien von Vertex stiegen gestern an der NASDAQ um 1,32 Prozent und schlossen bei 13,03 Dollar.

[NOBODY_III]

Kann es sein, daß die Meldung gestern in Amerika erst nach Börsenschluß gekommen ist?

Wie sonst ist ein Kursanstieg um lediglich 1,32 % zu verstehen?

Selbst die heutige Reaktion an deutschen Börsen hält sich in Grenzen, wenn man die jüngste Rallye bei Eckert &
Ziegler vergleichsweise betrachtet.

Demnach dürfen wir gespannt sein, was sich bei Vertex heute an der Nasdaq tut.

Vertex war auch immer eine Spezialität von Bernd Förtsch und der von ihm beratenen DAC-Fonds.
Jetzt wird er wohl die Werbetrommel wieder rühren.

[NOBODY_III]

/C O R R E C T I O N --Vertex PharmaceuticalsIncorporated/ 21.10. / 15:10


CAMBRIDGE, Mass., Oct. 21 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated today announced that the Food and Drug Administration (FDA) has granted marketing clearance for Lexiva(TM) (fosamprenavir calcium) (Lex-ee``-va, formerly GW433908, or 908), a new protease inhibitor (PI) for the treatment of HIV infection in adults in combination with other antiretroviral medications. The following points should be considered when initiating therapy with Lexiva/ritonavir (Lexiva/r) in PI-experienced patients: the PI-experienced patient study was not large enough to reach a definitive conclusion that Lexiva/r and lopinavir/ritonavir are clinically equivalent. Once-daily administration of Lexiva plus ritonavir is not recommended for PI-experienced patients. Lexiva was co-discovered by GlaxoSmithKline (GSK) and Vertex Pharmaceuticals Incorporated.

Lexiva, a PI that can be taken once or twice daily without food or water restrictions, has been evaluated in clinical trials with both PI-experienced and antiretroviral therapy (ART)-naive HIV patients.

Lexiva may be dosed three different ways: 1) two 700mg tablets twice daily (BID), 2) two 700mg tablets once daily (QD) in combination with two 100mg capsules of ritonavir QD (Lexiva/r QD), or 3) one 700mg tablet BID in combination with one 100mg capsule of ritonavir BID (Lexiva/r BID). For PI-experienced patients, the recommended dose is one 700mg tablet BID in combination with one 100mg capsule of ritonavir BID.

"The drug``s QD and BID dosing options with no food or water restrictions, and a low pill burden demonstrate GSK``s ongoing commitment to providing flexible anti-HIV therapies for patients," said Doug Manion, M.D., Vice President of Clinical Development and Medical Affairs at GSK.

More than 1,200 people -- both ART-naive and PI-experienced patients -- participated in three Phase III trials to test the safety and efficacy of Lexiva with and without ritonavir. In all three trials, study drugs were taken as part of combination therapy that included two nucleoside reverse transcriptase inhibitors. In these clinical trials Lexiva demonstrated:

* Durable anti-viral response through 48 weeks of therapy in ART-naive patients (<400 copies/mL 66% to 69%) * All grade 2-4 drug-related adverse events (less than or equal to) 10 percent in ART-naive patients - Significantly less grade 2-4 drug-related diarrhea than nelfinavir * All grade 2-4 drug-related adverse events (less than or equal to) 13 percent in PI-experienced patients * Flexible once or twice daily options in ART-naive patients with no food or fluid restrictions * No ART-naive patients receiving Lexiva/r developed any PI mutations. In PI-experienced patients, the following amprenavir resistance associated mutations were selected either alone or in combination: V32I, M46I/L, I47V, I47V, I50V, I54L/M and I84V. The clinical significance of resistance data is currently under evaluation.

"It``s important for patients to comply with therapy because current treatment is lifelong," said Jeffrey P. Nadler, M.D., Professor of Medicine and Director of Clinical Research in Infectious Diseases, University of South Florida College of Medicine, Tampa. "Patients need something they can tolerate, so that they are able to take the medicines as prescribed. Lexiva fits that picture," he said.

"Lexiva exemplifies Vertex``s focus on bringing forward new medicines for the treatment of serious diseases," said Joshua Boger, Ph.D., Chairman and CEO of Vertex Pharmaceuticals. "The approval of Lexiva highlights the productivity of the ten-year collaboration between Vertex and GlaxoSmithKline to discover, develop and commercialize new HIV protease inhibitors."

In conjunction with the approval announced today, Vertex earned a milestone payment from GlaxoSmithKline.

The following results were reported for each of the Phase III trials at 48 weeks:

The NEAT Study

NEAT compared Lexiva with nelfinavir (NFV) in 249 ethnically and gender diverse, ART-naive patients, with advanced HIV disease (45% of patients had viral load >100,000 copies/mL, 48% had CD4+ cell count <200 cells/mm(3), and 20% were CDC Class C) at entry. Patients took 1,400mg of Lexiva BID or 1,250mg of NFV BID in combination with abacavir sulfate and lamivudine BID.

* 66 percent of patients taking Lexiva achieved undetectable viral load (<400 copies/mL), compared to 52 percent of patients taking NFV. * Among patients with high baseline viral load (>100,000 copies/mL), 67 percent of 73 patients in the arm containing Lexiva achieved undetectable viral load (<400 copies/mL), compared to 36 percent of 37 patients in the NFV arm. * There was significantly less grade 2-4 drug-related diarrhea in patients receiving Lexiva (5 percent) than in patients receiving NFV (18 percent). * Protease mutations selected at the first failure timepoint with Lexiva (V32I+147V or 154L/M) had limited cross-resistance to other PIs. * The most common adverse events were diarrhea, nausea, vomiting, headache and rash. The SOLO Study

The SOLO Study reported results of 649 ethnically and gender diverse ART-naive patients with advanced HIV disease (43% of patients had viral load >100,000 copies/mL, 55% had CD4+ cell count <200 cells/mm(3), and 22% were CDC Class C) at entry. Patients in the study took either 1,400mg Lexiva with 200mg ritonavir (Lexiva/r) QD, or 1,250mg NFV BID. Both PIs were administered in combination with abacavir sulfate and lamivudine BID.

* 69 percent of patients taking Lexiva/r achieved undetectable viral load (<400 copies/mL), compared to 68 percent of patients taking NFV. * Among patients with a high viral load (>100,000 copies/mL) at baseline, 66 percent of 125 patients taking Lexiva/r QD achieved undetectable viral load (<400 copies/mL), compared to 64 percent of 133 patients taking NFV BID. * There was significantly less grade 2-4 drug-related diarrhea in patients receiving Lexiva (10 percent) than in patients receiving NFV (18 percent). * No protease mutations were observed through 48 weeks in the 32 patients who experienced virologic failure with Lexiva/r QD. * There were significantly fewer nucleoside reverse transcriptase inhibitor (NRTI) mutations observed after virologic failure with Lexiva/r QD (4 of 32 patients, or 13 percent) compared with NFV (30 of 54, or 56 percent). * The most common adverse events were diarrhea, nausea, vomiting, headache and rash. The CONTEXT Study

CONTEXT enrolled 315 PI-experienced patients with prior virologic failure. The study compared Lexiva with ritonavir to the PI lopinavir/ritonavir (LPV/r). The PIs were given in combination with two NRTIs. The following points should be considered when initiating therapy with Lexiva/r in PI- experienced patients: the PI-experienced patient study was not large enough to reach a definitive conclusion that Lexiva/r and lopinavir/ritonavir are clinically equivalent. Once-daily administration of Lexiva plus ritonavir is not recommended for PI-experienced patients.

* 58 percent of patients receiving Lexiva/r BID arm achieved undetectable viral load (<400 copies/mL) compared to 61 percent of patients taking LPV/r BID. * 46 percent of patients taking Lexiva/r BID achieved viral loads below 50 copies/mL compared to 50 percent taking LPV/r BID. * The overall incidence of drug-related adverse events of at least moderate severity was comparable between patients receiving Lexiva/r BID and LPV/r BID. * The most common adverse events were diarrhea, nausea, vomiting, headache and rash.

Lexiva is contraindicated in patients with previously demonstrated clinically significant hypersensitivity to any of the components of this product or to amprenavir. New onset or exacerbations of diabetes mellitus and hyperglycemia, and spontaneous bleeding in hemophiliacs have been reported with protease inhibitors. Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and "cushingoid appearance" have been observed in patients receiving antiretroviral therapy. The causal relationship, mechanism, and long-term consequences of these events are currently unknown. Lexiva is contraindicated with ergot derivatives, cisapride, pimozide, midazolam, and triazolam. If Lexiva is co-administered with ritonavir, flecainide and propafenone are also contraindicated.

GSK will market Lexiva, and GSK and Vertex will co-promote it in the United States and key markets in Europe.

GlaxoSmithKline is one of the world``s leading research-based pharmaceutical and healthcare companies and an industry leader in HIV research and therapies. The company is engaged in basic research programs designed to investigate new targets to treat HIV.

About Vertex

Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company``s strategy is to commercialize its products both independently and in collaboration with major pharmaceutical partners. Vertex``s product pipeline is principally focused on viral diseases, inflammation, autoimmune diseases and cancer. Vertex co-promotes the new HIV protease inhibitor Lexiva(TM) with GlaxoSmithKline.

Vertex Safe Harbor Statement

This press release may contain forward-looking statements. While management makes its best efforts to be accurate in making forward-looking statements, such statements are subject to risks and uncertainties that could cause Vertex``s actual results to vary materially. These risks and uncertainties include those risks listed under Risk Factors in Vertex``s form 10-K filed with the Securities and Exchange Commission on March 31, 2003.

Vertex``s press releases are available at http://www.vrtx.com/." target="_blank" rel="nofollow ugc noopener">http://www.vrtx.com/.

http://www.vrtx.com

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000119/VERTEXLOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, 888-776-6555 or 201-369-3467 Vertex Pharmaceuticals Incorporated

© PR Newswire

[Lifetrader]

http://data.island.com/ds/data/stockstats/stockstats.jsp?wid…

[Reimund11]

Guten Morgen
Hier geht es heute wohl extrem runter.
Rechne mit minus 29% zur eröffnung in europa, und mit eröffnung der us Börsen nochmal mit einen abschlag von 13%.
Müste bei uns zu 7,80 zu bekommen sein.
MFG Reimund
Der heute versucht zu zocken

[Reimund11]

Hier der Grund

Vertex Pharmaceuticals Reports Third Quarter 2003 Financial Results
CAMBRIDGE, Mass., Nov 10, 2003 (Canada NewsWire via COMTEX) -- Vertex
Pharmaceuticals Incorporated (Nasdaq: ) today reported consolidated
financial results for the three months ended September 30, 2003.

For the quarter ending September 30, 2003, the Company`s net loss, including a
charge of $42.4 million associated with lease restructuring, was $86.4 million,
or $1.12 per basic and diluted share, compared to a net loss of $33.5 million,
or $0.44 per basic and diluted share, in the quarter ending September 30, 2002.

Excluding restructuring and other expenses and gain on sale of assets, the loss
for the quarter ending September 30, 2003 was $44.5 million, or $0.58 per basic
and diluted share, compared to a net loss of $33.5 million, or $0.44 per basic
and diluted share, in the quarter ending September 30, 2002.

Total revenues for the three months ending September 30, 2003 were $18.4
million, compared to $34.3 million in 2002. Research and development expenses
for the three months ending September 30, 2003 were $50.0 million, compared to
$50.6 million for the third quarter of 2002. Sales, general and administrative
expenses for the three months ending September 30, 2003 were $10.0 million, as
compared to $12.9 million for third quarter of 2002.

The increased loss excluding restructuring and other expenses and gain on sale
of assets, decreased total revenue, and decreased SG&A expense for the three
months ending September 30, 2003 compared to the similar period last year were
mainly a result of the sale of certain assets and liabilities of PanVera LLC in
the first quarter of 2003 for approximately $95 million in cash.

The lease restructuring charge for the quarter ending September 30, 2003 was
$42.4 million. This charge reflects the anticipated incremental costs to exit a
real estate lease.

Other interest expense, net, for the quarter ending September 30, 2003 was $1.2
million. This compares to other interest income, net, of $2.4 million for the
third quarter of 2002, mainly reflecting lower portfolio yields.

At September 30, 2003, Vertex had approximately $596 million in cash, cash
equivalents and available for sale securities. Vertex has $315 million in
convertible debt due September 2007.

In October 2003, GlaxoSmithKline (GSK) and Vertex announced that the U.S. FDA
granted marketing clearance for Lexiva(TM) (fosamprenavir calcium), a new
protease inhibitor (PI) indicated in combination with other antiretroviral
agents for the treatment of HIV infection. Vertex announced today that GSK is
launching the drug in the U.S. this week. The companies anticipate that Lexiva
will be approved and launched in Europe in 2004.

Vertex also provided an update on its clinical development programs in two
additional press releases issued today, Monday, November 10, 2003. Investors
should review those press releases in conjunction with this third quarter 2003
financial results release.

Full Year 2003 Financial Guidance

This section contains forward-looking guidance about the financial outlook for
Vertex Pharmaceuticals. Financial guidance for 2003 is provided on a basis that
excludes the effect of charges associated with the Company`s restructuring and
other expenses and the gain on the sale of PanVera LLC`s technology and product
rights.

Vertex stated today that it has reduced its 2003 full year projections for
research and development investment to approximately $205 million for the full
year, reflecting cost savings of approximately $15 million from an operational
re-balancing performed in June 2003. Vertex also stated that it anticipates
total revenues for the full year would be approximately $80 million. The Company
is currently in discussions with pharmaceutical companies regarding strategic
research and product development agreements, and the timing and successful
conclusion of such discussions may result in additional revenue and cash flow in
2003. Vertex anticipates that SG&A expense for the full year 2003 will be
approximately $43 million. As a result of lower portfolio yields from Vertex`s
invested funds, the Company also anticipates an estimated $1 million of net
interest expense for the full year 2003. As a result of the above expectations,
Vertex`s loss, before certain charges and gains, is expected to be less than
$180 million for the full year 2003. Vertex expects cash, cash equivalents and
available for sale securities to be in excess of $550 million at the end of
2003.

"Vertex established the 2003 financial guidance based on an evaluation of our
core business objectives, our strategy for achieving those objectives, and the
Company`s financial profile," stated Ian Smith, Senior Vice President and Chief
Financial Officer of Vertex Pharmaceuticals. "Vertex will complete 2003 and move
into 2004 from a continuing strong financial position. We will preferentially
invest in proprietary products selected for late-stage development, we will
adjust our R&D investment based on the progression of our early-stage drug
candidates, and we will continue to seek pharmaceutical collaborations that are
aligned with our short and long-term needs."

Non-GAAP Financial Measures

In this press release, Vertex`s financial results are provided both in
accordance with generally accepted accounting principles (GAAP) in the United
States and using certain non-GAAP financial measures. In particular, Vertex
reports a third quarter loss, excluding restructuring and other expenses and
gain on sale of assets, which is a non-GAAP financial measure. Vertex also
provides guidance for a 2003 loss, excluding a lease restructuring charge and
other expenses and the gain on the sale of PanVera LLC technology and product
rights, of less than $180 million, which is a non-GAAP financial measure. These
results are provided as a complement to results provided in accordance with GAAP
because management believes these non-GAAP financial measures help indicate
underlying trends in the Company`s business, and uses these non-GAAP financial
measures to establish budgets and operational goals that are communicated
internally and externally, to manage the Company`s business and to evaluate its
performance.

About Vertex

Vertex Pharmaceuticals Incorporated is a global biotechnology company committed
to the discovery and development of breakthrough small molecule drugs for
serious diseases. The Company`s strategy is to commercialize its products both
independently and in collaboration with major pharmaceutical partners. Vertex`s
product pipeline is principally focused on viral diseases, inflammation,
autoimmune diseases and cancer. Vertex co-promotes the new HIV protease
inhibitor Lexiva(TM) (fosamprenavir calcium) with GlaxoSmithKline.

This press release may contain forward-looking statements, including statements
that (i) Lexiva will be approved and launched in Europe in 2004; (ii) Vertex
expects R&D expense, revenue, SG&A expense, net interest expense, and cash, cash
equivalents and available for sale securities to be as set forth above; (iii)
discussions with pharmaceutical companies regarding strategic research and
product development agreements may result in additional revenue and cash flow in
2003; and, (iv) Vertex will exit its real estate lease obligations. While
management makes its best efforts to be accurate in making forward-looking
statements, such statements are subject to risks and uncertainties that could
cause Vertex`s actual results to vary materially. These risks and uncertainties
include, among other things, the risks that Vertex`s internal and external drug
development programs will not proceed as planned, that Lexiva may not obtain
regulatory approval in Europe or that approval will be delayed, that clinical
trials for one or more of Vertex`s drug candidates may not proceed as planned
due to technical or patient enrollment issues, that Vertex will be unable to
realize its financial objectives due to any number of financial, technical or
partnership considerations, and other risks listed under Risk Factors in
Vertex`s form 10- K filed with the Securities and Exchange Commission on March
31, 2003.

Lexiva(TM) is a registered trademark of the GlaxoSmithKline group of companies.


Nun in Deutsch digital übersezt

Scheitelpharmaka berichtet drittes Viertel 2003 finanzielle Ergebnisse
Cambridge, Mass, Nov 10, 2003 (Kanada NewsWire über COMTEX) - Scheitel
Pharmaka integrierten (Nasdaq: )heute berichtet fundiert
finanzielle Ergebnisse für die drei Monate beendeten September 30, 2003.

Für das Viertel, das September 30, 2003, als der Nettoverlust, das Einschließen der Gesellschaft beendet, ein
Gebühr von $ 42,4 Millionen verband mit Mietvertragsumstrukturierung, war $ 86,4 Millionen
oder $ 1,12 pro Grundlage und verdünnten Anteil, die mit einem Nettoverlust an $ 33,5 Millionen verglichen sind
oder $ 0,44 pro Grundlage und verdünnten Anteil, die im Viertel September 30, 2002, beenden.

Außer Umstrukturierung und anderen Spesen und Gewinn auf Verkauf von Vermögenswerten, dem Verlust
für das Viertel, das September als 30 beendete, war 2003$ 44,5 Millionen oder $ 0,58 pro Grundlage
und mit einem Nettoverlust an $ 33,5 Millionen oder $ 0,44 pro Grundlage verglichener verdünnter Anteil
und verdünnter Anteil, der im Viertel September 30, 2002, beendet.

Totale Einnahmen für die drei Monate, die September als 30, 2003, beendeten, waren $ 18,4
Million, verglich mit $ 34,3 Millionen in 2002 . Forschungs- und Entwicklungsspesen
die drei Monate, endend, als September 30, 2003, $ 50,0 Millionen war, verglich zu
0$ 50,6 Millionen für das dritte Quartal von 2002 . Verkäufe allgemein und administrativ
Kosten für die drei Monate, die September als 30, 2003, beendeten, waren $ 10,0 Millionen als
verglichen für drittes Quartal von 2002 mit $ 12,9 Millionen.

Der gesteigerte Verlust außer Umstrukturierung und anderen Spesen und Gewinn auf Verkauf
von Vermögenswerten, verminderten totalen Einnahmen und verminderten SG & A Kosten für die drei
Monate, die September 30, 2003, mit dem ähnlichen Punktletzten Jahr verglichen beendeten, waren
hauptsächlich ein Ergebnis des Verkaufs von bestimmten Vermögenswerten und Verbindlichkeiten von PanVera LLC in
das erste Quartal von 2003 für ungefähr $ 95 Millionen in Bargeld.

Die Mietvertragsumstrukturierungsgebühr für das Viertel, das September als 30, 2003, beendete, war
$ 42,4 Millionen. Diese Gebühr reflektiert die erwarteten, zu verlassenden Grenzkosten ein
Immobilien mieten.

Anderer Interessenkosten, Netz für das Viertel, das September als 30, 2003, beendete, war $ 1,2
Million. Dies vergleicht mit Anderem Interesseneinkommen, Netz von $ 2,4 Millionen für d
drittes Quartal von 2002 gibt nach, hauptsächlich niedrigeres Portefeuille zu reflektieren.

Am 30. September 2003 hatte Scheitel ungefähr $ 596 Millionen in Bargeld, Bargeld
Äquivalente und für Verkaufssicherheiten verfügbar. Scheitel hat $ 315 Millionen ein
konvertierbare Schuld, die am September 2007 fällig ist.

Im Oktober 2003 kündigte GlaxoSmithKline (GSK) und Scheitel an daß das US-FDA
gewährte Marketingfreigabe für Lexiva (TM) (fosamprenavir Kalzium), ein neu
protease Hemmstoff (Pi) zeigte in Verbindung mit anderem antiretroviral an
Agenten für die Behandlung der HIV Infektion. Scheitel kündigte heute an, daß GSK ist
das Medikament in den USA diese Woche einführen. Die Gesellschaften erwarten daß Lexiva
wird in Europa in 2004 gebilligt und eingeführt.

Scheitel lieferte auch eine Aktualisierung auf seinen kalten Entwicklungsprogrammen in zwei
zusätzliche Pressemitteilungen gaben heute Montag November 10, 2003, aus . Anleger
sollte jene Pressemitteilungen in Verbindung mit diesem dritten Viertel 2003 überprüfen
finanzielle Ergebnisse geben frei.

Volle Jahr2003 finanzielle Führung

Dieser Abschnitt enthält vorausblickende Führung über den finanziellen Ausblick für
Scheitelpharmaka. Finanzieller Führung für 2003 wird auf einer Basis geliefert das
schließt aus, daß die Wirkung von Gebühren mit der Umstrukturierung der Gesellschaft verband, und
andere Spesen und der Gewinn auf dem Verkauf von PanVera LLCs Technologie und Produkt
Rechte.

Scheitel, der heute angegeben ist, wofür es seine 2003 vollen Jahrvorausplanungen reduziert hat
Forschungs- und Entwicklungsinvestition zu ungefähr $ 205 Millionen für d voll
Jahr, Kostenersparnisse ungefähr reflektieren $ 15 Millionen von ein betriebsbereit
wieder zu refl(nom__) ausbalanciern leistete im Juni 2003 . Scheitel gab auch an, daß es erwartet
totale Einnahmen für das volle Jahr wären ungefähr $ 80 Millionen. Die Gesellschaft
sind gegenwärtig in Diskussionen mit pharmazeutischen Gesellschaften betreffen strategisch
Forschungs- und Produktentwicklungsvereinbarungen und die Zeitberechnung und erfolgreich
Schluß von solchen Diskussionen kann zu Mehreinnahmen und Cash Flow führen in
2003 . Scheitel erwartet, daß SG & Kosten für das volle Jahr 2003 sein werden
ungefähr $ 43 Millionen. In Folge niedrigerer Portefeuilleausbeuten von Scheitel
investierte Gelder, die Gesellschaft erwartet auch einen geschätzten $ eine Million von Netz
interessieren Sie Kosten für das volle Jahr 2003 . in Folge der obengenannten Erwartungen
Der Verlust des Scheitels vor bestimmten Gebühren und Gewinnen wird erwartet, daß er weniger ist, als
0$ 180 Millionen für das volle Jahr 2003 . Scheitel erwartet Bar-, Baräquivalente und
für Verkaufssicherheiten, über $ 550 Millionen am Ende zu sein, verfügbar von
2003.

"Scheitel stellte fest, daß die 2003 finanzielle Führung auf einer Auswertung basierte von, unser
Kerngeschäftsziele, unsere Strategie für das Erreichen jener Ziele und d
Gesellschaft ist finanzielles Profil, "gab Ian Schmied, ältere Vizepräsidenten und Chef an
Finanzieller Offizier von Scheitelpharmaka. "Scheitel beendet 2003 und bewegt sich
in 2004 von einer kontinuierlichen starken finanziellen Position. Wir werden bevorzugt
investieren Sie in für späte Stufenentwicklung gewählte Eigentumsprodukte, wir werden
stellen Sie unsere R & D Investition basierend auf der Fortentwicklung von unserem früher Stufenmedikament ein
Kandidaten und wir fahren fort, pharmazeutische Kollaborationen zu suchen, die sind
richtete auf unseren kurzen und langfristigen Bedarf aus ".

Nicht-GAAP finanzielle Maße

In dieser Pressemitteilung werden den finanziellen Ergebnissen des Scheitels beide geliefert in
Übereinstimmung mit allgemein anerkannten Buchführungsprinzipien (GAAP) in d vereinigt sich
Staaten und das Verwenden von bestimmten Nicht-GAAP finanziellen Maßen. Vor allem, Scheitel
berichtet ein drittes Viertel über Verlust, nicht inbegriffene Umstrukturierung und andere Spesen und
holen Sie Verkauf von Vermögenswerten ein, der ein Nicht-GAAP finanzielles Maß ist. Scheitel auch
liefert Führung für einen 2003 Verlust, das Ausschließen eine Mietvertragsumstrukturierungsgebühr und
andere Spesen und der Gewinn auf dem Verkauf von PanVera LLC Technologie und Produkt
Rechte von weniger als $ 180 Millionen, das ein Nicht-GAAP finanzielles Maß ist. Diese
Ergebnisse werden geliefert, da eine Ergänzung von Ergebnissen entsprechend GAAP lieferte
weil Leitung diese Nicht-GAAP glaubt, helfen finanzielle Maße anzuzeigen
zugrundezuliegen verläuft im Geschäft der Gesellschaft und verwendet diese Nicht-GAAP finanziell
Maße, um Budgets und Betriebsziele einzuführen, die übermittelt sind
zu verwalten das Geschäft der Gesellschaft und zu beurteilen innerlich und äußerlich sein
Leistung.

Über Scheitel

Scheitelpharmaka integrierten ist eine globale Biotechnikgesellschaft entschlossen
zu der Entdeckung und Entwicklung des Durchbruchs betäubt kleines Molekül für
schwere Krankheiten. Die Strategie der Gesellschaft soll seine Produkte kommerzialisieren beide
unabhängig und in Kollaboration mit größeren pharmazeutischen Partnern. Scheitel-
Produktrohrleitung wird vornehmlich auf Viruskrankheiten, Entzündung gerichtet
autoimmune Krankheiten und Krebs. Scheitel co-fördert das neue HIV protease
Hemmstoff Lexiva (TM) (fosamprenavir Kalzium) mit GlaxoSmithKline.

Es kann sein, daß diese Pressemitteilung vorausblickende Erklärungen enthält, wenn sie Erklärungen einschließt
so (i) wird Lexiva in Europa in 2004 genehmigt und eingeführt; (ii) Scheitel
erwartet R & D Kosten, Einnahmen, SG & A Kosten, Nettointeressenkosten und Bargeld einlösen
Äquivalente und für Verkaufssicherheiten verfügbar, zu sein, wie heraus gesetzt; (iii)
Diskussionen mit pharmazeutischen Gesellschaften bezüglich strategischer Forschung und
Produktentwicklungsvereinbarungen können zu Mehreinnahmen und Cash Flow führen in
2003; und, (iv) Scheitel verläßt seine Immobilienmietvertragsverpflichtungen. Weile
Leitung macht seine besten Versuche, genau in Herstellung zu sein, vorausblickend
Erklärungen, solche Erklärungen sind Risiken und Ungewißheiten, die konnten, unterworfen
bewirken Sie, daß die tatsächlichen Ergebnisse des Scheitels materiell variieren. Diese Risiken und Ungewißheiten
schließen Sie unter anderen Dingen die Risiken ein, daß Scheitel internes und externes Medikament ist
Entwicklungsprogramme nicht fortfahren, als geplant, daß Lexiva nicht gelten kann
rechtliche Genehmigung in Europa oder dieses Einverständnis wird verzögert, so kalt sein
Prüfungen für eins oder mehr von den Medikamentenkandidaten des Scheitels können nicht fortfahren, als geplant
aufgrund technischer oder geduldiger Registrierungsangelegenheiten, zu denen Scheitel außerstande sein wird
merken Sie, daß seine durch irgendwelche verursachten finanziellen Ziele nummerieren von, finanziell, technisch oder
Partnerschaftsüberlegungen und andere Risiken führten unter Risikofaktoren auf ein
Die Form des Scheitels, die 10 K mit der Sicherheits- und Tauschkommission zum März ablegte
31, 2003.

Lexiva (TM) ist ein eingetragenes Warenzeichen der GlaxoSmithKline Gruppe von Gesellschaften.

MFG Reimund

[sukashi]

bei dieser reaktion bin ich auch der meinung dass sich hier rebound erwarten lässt.
heisse geschichte momentan-

reimund gute info
gruss
sukashi

[Reimund11]

Guten Tag
So, hatte Nachtschicht und heute Morgen ein update hier gemacht.
Die Aktuelle lage in USA ist nicht so schlecht.
Wer investiert war, für den schon fatal dieser abschlag.
Die Aktuellen Daten Plus realitime Chart
Name
Vertex Pharm

Last Price
8.8700

Net Change
-3.7800

Shares Matched
48,459

Orders Entered
374

Last Match Time
8:59:29.795
Market
NM

Previous Close
12.6500

Percent Change
-29.88%

Shares Entered
273,292

Open Orders
58

Last Order Time
8:59:26.345

Allen viel Glück

MFG Reimund

[Reimund11]

Ich hbe verbilligt
Kauf zu 7,48 MFG Reimund

[7clever]

VRTX mein Überraschungsei

Besprechungskurs:
$ 10.11







seven trade the trend

[7clever]

ich hab sie...

Kaufkurs : $ 9.89

seven sometines a fool

[7clever]

Vertex Researchers Publish Structure of Flt-3 Kinase in Molecular Cell
Thursday January 29, 12:15 pm ET
- Potential Mechanism Underlying Various Types of Leukemia Described -

CAMBRIDGE, Mass., Jan. 29 /PRNewswire-FirstCall/ -- Researchers from Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX - News) have published the first crystal structure of Flt-3, a member of the receptor tyrosine kinase family that is implicated in the development and progression of leukemia. This research was published in the January 30th issue of the scientific journal Molecular Cell. The study provides direct insight into the mechanism by which mutated forms of the Flt-3 receptor can activate themselves and trigger uncontrolled proliferation of immature blood cells, a common feature of several types of leukemia. Based on an analysis of the crystal structure, Vertex scientists hypothesize that specific mutations cause Flt-3`s juxtamembrane domain to adopt a conformation that enables the receptor to phosphorylate itself, resulting in uncontrolled cellular proliferation.

"Several research groups have already demonstrated that a mutated form of Flt-3 can activate itself, and our analysis of the crystal structure suggests how this can occur," commented James Griffith, Staff Investigator at Vertex and lead author of the study. "Given the genetic and structural homology among the receptor tyrosine kinase family, and the overactivation of these receptor kinases in many tumor types, we may speculate that the mechanism we have identified may have broad implications for the development of small molecule cancer therapies."

Flt-3 is primarily expressed in immature hematopoietic cells, which are responsible for generating blood cells, and is essential for the normal function of stem cells and the immune system. Growth and proliferation of blood cells is, in part, accomplished through the controlled stimulation of receptor tyrosine kinases, such as Flt-3, which propagate a growth signal to other proteins in a biological pathway. Mutations in Flt-3 are most common in acute myeloid leukemia (AML), and they are associated with a poor prognosis of disease. Exploring the mechanism by which these Flt-3 mutations cause uncontrolled proliferation through their overactive state may provide insights for the design and development of new small molecule drugs.

"The findings of this study are very intriguing, and we believe they may open a window of opportunity for the design of new drugs that address the mechanism of mutated FLT-3, in leukemia patients, as well other cancer types where tyrosine kinases use the same mechanism," said Peter Mueller, Ph.D., Chief Scientific Officer of Vertex.

About Leukemia and FLT-3

Flt-3 is expressed in high levels in a wide range of leukemias, including 70-100% of acute myelogenous leukemia (AML), lymphoblastic leukemia (ALL), and myelogenous leukemia (CML). Furthermore, activating Flt-3 mutations are present in up to 40% of AML patients. The mutated form of this tyrosine kinase is believed to promote uncontrolled growth of abnormal immature blood cells that crowd out the normal cells, leading to deadly forms of leukemia. According to the American Cancer Society, in 2003, 30,600 patients were diagnosed in the United States with leukemia, more than a third of whom have AML. The American Cancer Society estimates that AML resulted in 7800 deaths in the United States in 2003.

The authors of the Molecular Cell paper, titled "The Structural Basis for Autoinhibition of FLT-3 by the Juxtamembrane Domain," are James Griffith, James Black, Carlos Faerman, Lora Swenson, Michael Wynn, Fan Lu, Judith Lippke, and Kumkum Saxena, all of Vertex.

About Vertex

Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company`s strategy is to commercialize its products both independently and in collaboration with major pharmaceutical partners. Vertex`s product pipeline is principally focused on viral diseases, inflammation, autoimmune diseases and cancer. Vertex co-promotes the new HIV protease inhibitor, Lexiva(TM), with GlaxoSmithKline.

Vertex Safe Harbor Statement

This press release may contain forward-looking statements, including statements that the research findings for Flt-3 may have broad implications for the development of small molecule cancer therapies, and that insights into the Flt-3 mechanism may provide an opportunity to design novel anti-cancer therapies. While management makes its best efforts to be accurate in making forward-looking statements, such statements are subject to risks and uncertainties that could cause Vertex`s actual results to vary materially. These risks and uncertainties include those risks listed under Risk Factors in Vertex`s form 10-K filed with the Securities and Exchange Commission on March 31, 2003.

Vertex Contacts:

Lynne H. Brum, VP, Corporate Communications and Financial Planning, [phone]

Michael Partridge, Director, Corporate Communications, [phone]


Source: Vertex Pharmaceuticals Incorporated

[7clever]

Events Calendar:

Feb 3: Merill Lynch Conference in New York. Vertex will present at 4:45pm ET.
----------------------

[7clever]

wilde Diskussionen auf

http://finance.yahoo.com/q/mb?s=VRTX

Beachtlich das Volumen und der Kurs zu Börsenbeginn in USA...

ein interessanter Intradaychart

seven

[7clever]

Vertex and Novartis Amend Drug Discovery and Development Collaboration

CAMBRIDGE, Mass., Feb. 3 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated(NASDAQ-NMS:VRTX) (Nasdaq: VRTX) today announced that Vertex and Novartis Pharma AG have amended their collaboration directed at targets in the protein kinase gene family.

The revised agreement provides for a more rapid and earlier stage transfer of the drug candidates discovered by Vertex to Novartis for clinical development. Vertex will continue to be responsible for drug discovery. Novartis is able to pursue research in the kinase field independently of Vertex. Under the amended agreement, Novartis will have the responsibility for preclinical and full clinical development. Novartis will also continue to provide research funding to Vertex until the end of the research term in 2006. Vertex will receive milestone payments based on Novartis` acceptance and clinical advancement of drug development candidates.

"We are pleased to continue our partnership with Vertex," said Dr. Joerg Reinhardt, Head of Pharma Development, Novartis Pharma AG. "The revised structure of this collaboration will enable earlier compound transfer to Novartis, with resulting control of clinical development of novel medicines by Novartis in critical areas of medical need, including cancer and autoimmune disease."

"This earlier transfer of drug candidates to Novartis will provide Vertex with greater development capacity to invest in its independently owned drug candidates," said Joshua Boger, Ph.D., Chairman and CEO of Vertex Pharmaceuticals. "The drug candidates discovered under the collaboration and transferred to Novartis will provide Vertex with an earlier opportunity to achieve preclinical and clinical milestones."

Through 2006, Vertex expects to recognize additional research revenue of approximately $100 million. Under the revised agreement, Vertex will nominate preclinical drug candidates for acceptance by Novartis. Vertex may receive up to $35 million in license fees and milestones for each preclinical drug candidate accepted by Novartis, assuming successful development and product registration, including $10 million upon the initial acceptance of each preclinical drug candidate. Vertex`s entitlement to receive royalties on sales of products that are commercialized as part of the collaboration is unchanged from the earlier agreement. Novartis has exclusive worldwide development, manufacturing and marketing rights for the preclinical drug candidates it accepts from Vertex.

Progress in Kinase Research

Protein kinases are enzymes that play a key role in propagating biochemical signals in many different biological pathways. More than 500 kinases have been described in scientific literature, and specific kinases have been implicated in a wide range of diseases, including cancer, cardiovascular disease, inflammatory disease, and neurological disease. As such, kinases represent important control points for small molecule therapeutic intervention. To accelerate drug discovery in the kinase gene family and other gene families, Vertex has pioneered a parallel approach to drug design which groups protein targets according to structural similarity, in order to leverage medicinal chemistry efficiently and increase the output of novel drugs for a variety of major diseases.

Following initiation of the research collaboration with Novartis in May 2000, Vertex has conducted extensive drug discovery research across the kinase gene family. Vertex researchers have determined the atomic structure of more than 20 novel kinase drug targets and more than 300 kinase/inhibitor co- complexes, providing information to accelerate drug design and furthering scientific understanding of the role kinases play in disease. Most recently, Vertex researchers published structural interpretations of how mutations in kinases like Flt-3 can lead to uncontrolled cellular proliferation and cancer. Using proprietary in silico and in vitro methodologies, Vertex has designed an expanded and diverse library of proprietary kinase inhibitors, leading to the filing of more than 90 patents covering many hundreds of distinct chemical scaffolds.

To date, Vertex has advanced three small molecule kinase inhibitors as potential development candidates: VX-680 and VX-528 for oncology indications, and VX-608 for neurological disease. Novartis will have an option to develop VX-608 under the terms of the amended agreement. Vertex may opt to continue development of VX-680 and VX-528 under the terms of the original agreement, or to develop and commercialize these drug candidates independently. Vertex expects to advance multiple additional compounds into preclinical development in 2004, principally directed at cancer, inflammation, and autoimmune disease.

About Vertex

Vertex Pharmaceuticals Incorporated(NASDAQ-NMS:VRTX) is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company`s strategy is to commercialize its products both independently and in collaboration with major pharmaceutical partners. Vertex`s product pipeline is principally focused on viral diseases, inflammation, autoimmune diseases and cancer. Vertex co-promotes the new HIV protease inhibitor, Lexiva(TM), with GlaxoSmithKline.

This press release may contain forward-looking statements, including statements that (i) the revised structure of the collaboration will enable the more rapid clinical development of novel medicines; (ii) research progress in the kinase area has the potential to provide Vertex with near-term revenue opportunities; (iii) Vertex may receive up to $35 million in pre-commercial payments for each drug candidate accepted by Novartis; and (iv) Vertex`s approach to drug design can effectively increase the output of novel drugs for a variety of major diseases. While management makes its best efforts to be accurate in making forward-looking statements, such statements are subject to risks and uncertainties that could cause Vertex`s actual results to vary materially. These risks and uncertainties include, among other things, the risk that the agreement does not continue to completion, that Vertex may not be successful in identifying novel kinase inhibitors for transfer to Novartis, that Novartis may not accept compounds proposed by Vertex, that clinical trials of Vertex`s kinase inhibitors may not proceed as planned due to technical, scientific, or patient enrollment issues, that clinical results of Vertex`s kinase inhibitors will not reflect positive preclinical results and other risks listed under Risk Factors in Vertex`s form 10-K filed with the Securities and Exchange Commission on March 31, 2003.

Lexiva(TM) is a registered trademark of the GlaxoSmithKline group of companies.

Vertex`s press releases are available at www.vrtx.com.

Vertex Contacts:

Lynne H. Brum, VP, Corporate Communications and Financial Planning, [phone]

Michael Partridge, Director, Corporate Communications, [phone]

SOURCE Vertex Pharmaceuticals Incorporated(NASDAQ-NMS:VRTX)

-0- 02/03/2004
/CONTACT: Lynne H. Brum, VP, Corporate Communications and Financial
Planning, [phone], or Michael Partridge, Director, Corporate
Communications, [phone], both of Vertex/
/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000119/VERTEXLOGOhttp:…
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 201-369-3467/
/Company News On-Call: http://www.prnewswire.com/comp/938395.html/" target="_blank" rel="nofollow ugc noopener">http://www.prnewswire.com/comp/938395.html/
/Web site: http://www.vrtx.com/
(VRTX)

CO: Vertex Pharmaceuticals Incorporated(NASDAQ-NMS:VRTX)
; Novartis Pharma AG
ST: Massachusetts
IN: MTC BIO
SU:

CP-EO
-- NETU035 --
3570 02/03/200416:05 ESThttp://www.prnewswire.com

[7clever]

Vertex Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference

Company to Provide Financial Guidance for 2004

CAMBRIDGE, Mass., Feb. 3 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated(NASDAQ-NMS:VRTX) (Nasdaq: VRTX) will review its 2004 outlook and provide its 2004 financial guidance at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference in New York today, Tuesday, February 3, 2004. The update will be presented by Joshua Boger, Ph.D., Chairman and CEO of Vertex Pharmaceuticals. A live audio webcast of the presentation will be available on Vertex`s website, www.vrtx.com, at 4:10 pm ET, February 3, 2004. An archived audio webcast of the presentation will be available on Vertex`s website through February 16, 2004.

"In 2004, Vertex expects to make important advances with our antiviral and inflammation product portfolio," stated Dr. Boger. "In particular, we believe that our drug candidates in development targeting HCV, merimepodib and VX-950, represent significant medical and commercial opportunities. We believe that focused investment in our proprietary drug candidates in 2004, combined with our pharmaceutical partners` investment in Vertex`s products, will position the Company for significant long-term value creation and commercial success."

Dr. Boger continued, "In addition to investing in our clinical activities, we also will continue to cultivate the creative and innovative work being done in our discovery organization. In 2004, we anticipate advancing novel preclinical drug candidates from our ion channel and kinase research programs. Importantly, our amended kinase collaboration with Novartis will provide us with an earlier opportunity to achieve clinical milestones and also will provide us with flexibility to dedicate development resources to our proprietary drug candidates."

2004 Corporate Goals:

Vertex`s milestones for 2004 were established to enable the Company to advance its business toward its objective of sustained value creation. Specifically, Vertex expects to:

* Advance HIV franchise with partner GlaxoSmithKline
-- Launch the new HIV protease inhibitor Lexiva(TM) in Europe.
-- Begin Phase II development of investigational HIV protease inhibitor
VX-385.
* Advance proprietary HCV pipeline
-- Initiate advanced clinical development of oral HCV therapy
merimepodib in combination with ribavirin and pegylated interferon.
-- Initiate Phase I development of oral HCV protease inhibitor VX-950 in
healthy volunteers in 1H `04; initiate clinical evaluation of VX-950
in HCV patients in 2H `04.
-- Advance second-generation HCV compounds into preclinical development.
* Advance inflammation pipeline
-- Complete pilot Phase II trial of p38 MAP kinase inhibitor VX-702 for
acute coronary syndromes (ACS).
-- Initiate Phase II development of oral ICE inhibitor VX-765.

-- Complete toxicology evaluation for pralnacasan in partnership with
Aventis.
* Invest in discovery organization
-- Select new preclinical drug candidates in kinase and voltage-gated
sodium ion channel research programs.

* Establish new pharmaceutical collaborations targeting the following areas:

-- Vertex proprietary compounds targeting HCV and inflammatory disease
(merimepodib, VX-950, VX-765): Establish collaborations to support
development and commercialization outside of North America.
-- Vertex proprietary compounds in selected therapeutic areas (VX-944,
VX-702): Establish collaborations to support development and
commercialization in worldwide markets.
-- Vertex discovery organization: Establish collaborations to support
ion channel, GPCR and bacterial gyrase programs.

Full Year 2004 Financial Guidance

This section contains forward-looking guidance about the financial outlook for Vertex Pharmaceuticals. At today`s conference, Vertex will provide financial guidance for 2004 on a basis that excludes any charges and gains. The Company also will reiterate its guidance for a full-year 2003 loss of less than $180 million, before any charges and gains. In 2003, Vertex engaged in activities that resulted in gains on the sale of PanVera LLC and Aurora Instruments, as well as charges related to operational restructuring and lease restructuring. The charge associated with the estimated costs of lease restructuring may be updated quarterly, until the restructuring of the lease is completed.

"Vertex is focused on executing our business strategy, which is to bring Vertex-discovered drugs to the market both independently and with partners," stated Ian Smith, Senior Vice President and Chief Financial Officer of Vertex Pharmaceuticals. "Maintaining our financial strength is a key component of this strategy. We are confident that our financial guidance for 2004, which was based on an evaluation of our business objectives, and our strategy for achieving those objectives, will pave the way to our ultimate objective of profitability and sustained profit growth."

* Loss: Vertex expects that the full year 2004 loss will be in the range
of $140 to $150 million, before any gains or charges, specifically,
completion of a lease restructuring.
* Revenues: Total revenue will be in the range of $90 to $100 million in
2004. This will be comprised of $60 to $65 million in committed funding
and milestones from existing collaborative partners, and $15 to $18
million from HIV product royalties. In addition, the Company is
currently in discussions with pharmaceutical companies regarding
strategic research and product development agreements, and the
successful conclusion of such discussions may result in additional
revenue and cash flow in 2004.
* Research and Development (R&D) Expense: As Vertex prioritizes its
investment toward proprietary drug candidates and realizes the benefits
from an operational restructuring during 2003 in drug discovery, the
Company projects that R&D costs will be in the range of $190 to $205
million for the full year of 2004.
* Sales, General and Administrative (SG&A) Expense: Vertex expects SG&A
to be in the range of $38 to $43 million in 2004.
* Cash, Cash Equivalents, and Available for Sale Securities: Vertex
expects cash, cash equivalents and available for sale securities to be
in excess of $350 million at the end of 2004.
* Shares Outstanding: Vertex expects to have approximately 79 million
weighted average shares outstanding at year-end 2004.

Mr. Smith continued, "In 2004, we are focused on reducing our loss by increasing revenue from multiple sources: funding from existing collaborative partners, by achieving milestones under our revised collaboration with Novartis and our GSK HIV collaboration; and from increased royalties from Lexiva, as we benefit from a successful worldwide product launch. In addition, we have focused our development investment toward compounds targeting HCV and inflammatory disease, and will gain the financial benefit in our discovery organization from an operational restructuring that occurred in 2003."

Non-GAAP Financial Measures

In this press release, Vertex`s financial results are provided both in accordance with generally accepted accounting principles (GAAP) in the United States and using certain non-GAAP financial measures. In particular, Vertex provides guidance for a 2003 and 2004 loss, excluding any charges or gains, which are non-GAAP financial measures. These results are provided as a complement to results provided in accordance with GAAP because management believes these non-GAAP financial measures help indicate underlying trends in the Company`s business, and uses these non-GAAP financial measures to establish budgets and operational goals that are communicated internally and externally, to manage the Company`s business and to evaluate its performance.

About Vertex

Vertex Pharmaceuticals Incorporated(NASDAQ-NMS:VRTX) is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company`s strategy is to commercialize its products both independently and in collaboration with major pharmaceutical partners. Vertex`s product pipeline is principally focused on viral diseases, inflammation, autoimmune diseases and cancer. Vertex co-promotes the new HIV protease inhibitor Lexiva(TM) (fosamprenavir calcium) with GlaxoSmithKline.

This press release may contain forward-looking statements, including statements that (i) Vertex expects to make important advances with its antiviral and inflammation product portfolio, (ii) its drug candidates targeting HCV represent significant medical and commercial opportunities, (iii) the corporate goals set forth above will be achieved as described, (iv) Vertex expects its loss before gains and charges, revenue, R&D expense, SG&A expense, cash, cash equivalents and available for sale securities and shares outstanding for 2004 to be as set forth above; (v) discussions with pharmaceutical companies regarding strategic research and product development agreements may result in additional revenue and cash flow in 2004, and (vi) Vertex will exit its real estate lease obligations. While management makes its best efforts to be accurate in making forward-looking statements, such statements are subject to risks and uncertainties that could cause Vertex`s actual results to vary materially. These risks and uncertainties include, among other things, the risks that clinical and commercial goals, including the approval of Lexiva in the EU and the advancement of clinical trials for various drug candidates, may not be achieved due to scientific, commercial or regulatory issues or concerns, or patient enrollment delays, that Vertex will be unable to realize its financial objectives due to any number of financial, technical or partnership considerations, that Vertex will be unsuccessful in attracting new partners for its ongoing discovery and development programs, that Vertex will be unable to successfully conclude a restructuring of its lease obligations and other risks listed under Risk Factors in Vertex`s form 10-K filed with the Securities and Exchange Commission on March 31, 2003.

Lexiva is a registered trademark of the GlaxoSmithKline group of companies.

Conference Call and Webcast: Year End 2003 Financial Results:

Vertex Pharmaceuticals will host a conference call on February 11, 2004 at 5:00 p.m. ET to review financial results and recent developments. This call will be broadcast via the Internet at www.vrtx.com in the investor center. Alternatively, to listen to the call on the telephone, dial [phone] (U.S. and Canada) or [phone] (International).

The call will be available for replay via telephone commencing February 11, 2004 at 8:00 p.m. ET running through 5:00 p.m. ET on February 20, 2004. The replay phone number for the U.S. and Canada is [phone]. The international replay number is [phone] and the conference ID number is 5279512. Following the live webcast, an archived version will be available on Vertex`s website until 5:00 p.m. ET on February 20, 2004.

Vertex`s press releases are available at www.vrtx.com.

Vertex Contacts:

Lynne H. Brum, Vice President, Corporate Communications and Financial Planning, [phone]

Michael Partridge, Director, Corporate Communications, [phone]

SOURCE Vertex Pharmaceuticals Incorporated(NASDAQ-NMS:VRTX)

-0- 02/03/2004
/CONTACT: Lynne H. Brum, Vice President, Corporate Communications and
Financial Planning, [phone], or Michael Partridge, Director, Corporate
Communications, [phone] both of Vertex/
/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000119/VERTEXLOGOhttp:…
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 201-369-3467/
/Company News On-Call: http://www.prnewswire.com/comp/938395.html/" target="_blank" rel="nofollow ugc noopener">http://www.prnewswire.com/comp/938395.html/
/Web site: http://www.vrtx.com/
(VRTX)

CO: Vertex Pharmaceuticals Incorporated(NASDAQ-NMS:VRTX)

ST: Massachusetts
IN: MTC BIO
SU: TDS

EO-AL
-- NETU031 --
3580 02/03/200416:07 ESThttp://www.prnewswire.com

[7clever]

Überblick:

-------------

+DJ Vertex And Novartis Amend Drug Discovery And Development Collaboration

02/03/2004
Dow Jones News Services
(Copyright © 2004 Dow Jones & Company, Inc.)



(MORE) Dow Jones Newswires

02-03-04 1605ET

*DJ Vertex: Plan Transfers Drug Candidates To Novartis Sooner



(MORE) Dow Jones Newswires

02-03-04 1609ET

*DJ Vertex: Novartis Will Oversee Preclinical, Clinical Devt



(MORE) Dow Jones Newswires

02-03-04 1610ET

*DJ Vertex Sees Added Research Rev Of $100M Through 2006 >VRTX



(MORE) Dow Jones Newswires

[7clever]

Event: Year End 2003 Financial Results
Start Date: Feb 11, 2004
Start Time: 05:00 PM

[7clever]

Vertex Pharmaceuticals Announces Issuance of Convertible Notes Due 2011 in Exchange for $153.5 Million of its Convertible Notes Due 2007
February 10, 2004 09:28:00 AM ET

CAMBRIDGE, Mass., Feb. 10 /PRNewswire-FirstCall/-- Vertex Pharmaceuticals Incorporated VRTX announced today that five holders of its existing 5% Convertible Subordinated Notes due 2007 have agreed to exchange approximately $153.5 million in aggregate principal amount of such existing Notes for approximately $153.5 million in aggregate principal amount of newly issued 5.75% Convertible Senior Subordinated Notes due 2011. The Senior Subordinated Notes were issued through a private offering to qualified institutional buyers. The exchange is expected to close on February 13, 2004. The Senior Subordinated Notes are convertible into Vertex Common Stock at a price equal to $14.94 per share, subject to adjustment in certain circumstances, which represents a 55% premium over the average closing price of the Vertex Common Stock over a four-day period ending on Friday, February 6, of $9.64. The Senior Subordinated Notes bear an interest rate of 5.75% per annum, have a seven-year term and can be redeemed by Vertex on or after February 15, 2007.

With the completion of this transaction, Vertex will have $161.5 million in aggregate principal amount of its existing 5% Convertible Notes due 2007 and $153.5 million in aggregate principal amount of its new 5.75% Convertible Senior Subordinated Notes due 2011.

Vertex has agreed to file a registration statement for the resale of the new Notes and the shares of Common Stock issuable upon conversion of the new Notes within 120 days after the closing of the offering.

This announcement is neither an offer to exchange nor a solicitation of an offer to exchange any of these securities.

The New Notes and the Common Stock issuable upon conversion of the new Notes have not been registered under the Securities Act of 1933 or any state securities laws, and are being offered only to qualified institutional buyers in transactions not subject to the registration requirements of the Securities Act. Unless so registered, the New Notes and the Common Stock issued upon conversion of the New Notes may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws.

Vertex Contacts:
Lynne H. Brum, VP, Corporate Communications and Financial Planning,
[phone]
Michael Partridge, Director, Corporate Communications, [phone]

© 2004 PRNewswire

[7clever]

Market Report -- In Play (VRTX)
February 11, 2004 4:08:00 PM ET

Vertex Pharm beats by $0.03 (VRTX) 10.18 +0.01: Reports Q4 (Dec) loss of $0.51 per share, $0.03 better than the Reuters Research consensus of ($0.54); revenues fell 18.2% year/year to $21.4 mln vs the $21.7 mln consensus. Co expects total revenue for 2004 will be $90-$100 mln vs consensus of $94 mln.

Briefing.com is the leading Internet provider of live market analysis for U.S. Stock, U.S. Bond, and world FX market participants.
Read more In Play articles

[7clever]

Äpfel und Birnen
VRTX in EUR / $



seven

[7clever]

hat sich mal wieder gelohnt

seven trade to win

[7clever]

Settlement Date:Short Interest:Avg Daily:Share Volume: Days to Cover

Jan. 15, 2004 3,853,336 741,548 5.20
Dec. 15, 2003 4,161,408 813,262 5.12
Nov. 14, 2003 3,786,126 1,363,471 2.78
Oct. 15, 2003 3,572,037 706,844 5.05
Sep. 15, 2003 2,974,670 601,501 4.95
Aug. 15, 2003 3,813,288 632,196 6.03
Jul. 15, 2003 4,305,311 850,428 5.06
Jun. 13, 2003 3,607,583 861,230 4.19
May 15, 2003 3,709,349 637,545 5.82
Apr. 15, 2003 3,460,765 784,343 4.41
Mar. 14, 2003 2,689,401 712,588 3.77
Feb. 14, 2003 2,759,630 701,554 3.93

[7clever]

Reuters
Vertex drug reverses cancer in animal study
Sunday February 22, 1:00 pm ET

NEW YORK, Feb 22 (Reuters) - A new type of cancer drug stopped tumor growth in an early animal study, boosting hopes that the approach may prove promising in humans, according to data released on Sunday.

The treatment, called VX-680 and being developed by Vertex Pharmaceuticals Inc. (NasdaqNM:VRTX - News), represents the first drug to stop tumors by targeting enzymes called Aurora kinases.

Research has showed that Aurora kinases play an important role in mitosis, or the process of cell division, which is out of control in cancer patients. Aurora kinases have been identified as overly abundant in certain types of cancer, such as leukemia, colon cancer and breast cancer.

Many proteins are overexpressed in cancer cells, and stopping the overexpression will not necessarily have any impact on halting cancer, as has been observed in many clinical trial failures.

But the Vertex drug showed robust results in mice and rats.

In the animal study, the drug on average showed a 56 percent regression in colon cancer tumors after just 10 days, while in pancreatic cancer, the regression was 22 percent.

"One of the exciting things we have found is that we`ve tested the compound against a number of different tumor types, including those that are very difficult to treat in man, and we`ve had success against all of them so far," said Karen Miller, a principal researcher at Vertex and senior author of the study, published in the March issue of Nature Medicine.

A spokesman for Vertex said the company intends to start testing the treatment in humans in early-stage studies before the end of the year.

VX-680 is considered a "small molecule," or a mix of chemicals in a tight bundle, unlike most new cancer drugs, which are "large molecules," or proteins.

[7clever]

Wo kommen eigentlich die ganzen Leutz her? Es war hier immer so ruhig

seven

What is going on? I didn`t expect the
by: chavis_maclemore 02/23/04 03:32 pm
Msg: 5505 of 5509

price to increase and hold due to the trials being conducted on mice. Could it be they are going to bypass human testing and just sell the drug to veterinarians? Anyone know just what kind of market there is for cancer in pets...especially mice?

[7clever]

Vertex Pharmaceuticals Announces Webcast of its Presentation at the 6th Annual Bio CEO & Investor Conference

Cambridge, MA, February 24, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) will webcast its corporate presentation at the 6th Annual BIO CEO & Investor Conference on Wednesday, February 25, 2004 at the Waldorf-Astoria Hotel in New York City. N. Anthony Coles, M.D., Vertex’s Senior Vice President, Commercial Operations will present a corporate update at 11:30AM. In addition, Dr. Coles will participate in an industry focus session on new approaches to the treatment of hepatitis C viral (HCV) infection at 9:30AM.

The presentation will be webcast live and may be accessed by visiting the Vertex website at www.vrtx.com. A replay of the webcast will also be available on the Company’s website until March 3, 2004.

About Vertex
Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company’s strategy is to commercialize its products both independently and in collaboration with major pharmaceutical partners. Vertex’s product pipeline is principally focused on viral diseases, inflammation, autoimmune diseases and cancer. Vertex co-promotes the new HIV protease inhibitor, Lexiva™, with GlaxoSmithKline. Lexiva™ is a trademark of the GlaxoSmithKline group of companies.

Vertex Contacts:
Michael Partridge, Director, Corporate Communications, [phone]

[7clever]

Nachdem die Ratten äeh Mäuse hier mal wieder zu langsam waren

Feb 25: Vertex presents at the 6th Annual Bio CEO & Investor Conference.
Listen to live Webcast; 9:30am EST & 11:30am EST.

[LMeister7]

Morjen,
hoffentlich landet die ganze Kohle nicht bei den PharmaGeyern! Wat tut eigentlich die EU. Auch in Osteuropa grassiert die Lustseuche.
______________________________________________
Bush will mit Milliarden Dollar gegen Aids kämpfen
USA
Mit 15 Milliarden Dollar will US-Präsident Bush dem weltweiten Kampf gegen Aids neuen Schwung verleihen. Vorgesehen sind vorbeugende Maßnahmen sowie die Versorgung von Infizierten in den 14 am stärksten betroffenen Ländern. Außerdem sollen Projekte in mehr als 100 Ländern unterstützt werden, an denen sich die Empfänger aber auch selbst beteiligen müssen. Eine erste Tranche wurde jetzt freigegeben. AP
_________________________________________________

MfG,
LM7

[7clever]

update
Settlement Date Short Interest Avg Daily Share Volume Days to Cover
Feb. 13, 2004 4,205,787 771,221 5.45
Jan. 15, 2004 3,853,336 741,548 5.20
Dec. 15, 2003 4,161,408 813,262 5.12
Nov. 14, 2003 3,786,126 1,363,471 2.78
Oct. 15, 2003 3,572,037 706,844 5.05
Sep. 15, 2003 2,974,670 601,501 4.95
Aug. 15, 2003 3,813,288 632,196 6.03
Jul. 15, 2003 4,305,311 850,428 5.06
Jun. 13, 2003 3,607,583 861,230 4.19
May 15, 2003 3,709,349 637,545 5.82
Apr. 15, 2003 3,460,765 784,343 4.41
Mar. 14, 2003 2,689,401 712,588 3.77